1. Stuhldreher N, Konnopka A, Wild B, Herzog W, Zipfel S, Löwe B, et al. Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review. Int J Eat Disord. 2012;45:476–91.
2. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312:2265–76.
3. Orphanet. Prevalence of rare diseases: bibliographic data. 2014 May. Report No.: 1. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf . Accessed 1 Nov 2015.
4. European Commission. European Commission Regulation (EC) no. 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. 1999 Dec 16. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf . Accessed 11 Dec 2015.
5. US Government Publishing Office. US Code § 360bb—designation of drugs for rare diseases or conditions. 2011 Jan 7. https://www.gpo.gov/fdsys/granule/USCODE-2010-title21/USCODE-2010-title21-chap9-subchapV-partB-sec360bb/content-detail.html . Accessed 11 Dec 2015.